Identification of STRBP as a Novel JAK2 Fusion Partner Gene in a Young Adult With Philadelphia Chromosome-Like B-Lymphoblastic Leukemia

被引:7
|
作者
Zhang, Xin-Yue [1 ,2 ]
Dai, Hai-Ping [1 ,2 ]
Li, Zheng [1 ,2 ]
Yin, Jia [1 ,2 ]
Lang, Xing-Ping [3 ]
Yang, Chun-Xiao [3 ]
Xiao, Sheng [4 ]
Zhu, Ming-Qing [1 ,2 ]
Liu, Dan-Dan [1 ,2 ]
Liu, Hong [1 ,2 ]
Shen, Hong-Jie [1 ,2 ]
Wu, De-Pei [1 ,2 ]
Tang, Xiao-Wen [1 ,2 ]
机构
[1] Soochow Univ, Natl Clin Res Ctr Hematol Dis, Jiangsu Inst Hematol, Affiliated Hosp 1, Suzhou, Peoples R China
[2] Soochow Univ, Inst Blood & Marrow Transplantat, Collaborat Innovat Ctr Hematol, Suzhou, Peoples R China
[3] Sano Suzhou Precis Med Co Ltd, Suzhou, Peoples R China
[4] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
来源
FRONTIERS IN ONCOLOGY | 2021年 / 10卷
基金
国家重点研发计划; 中国国家自然科学基金;
关键词
fusion gene; STRBP-JAK2; Ph-like; chimeric antigen receptor; B-lymphoblastic leukemia; BINDING PROTEIN; KINASE; STRATEGIES;
D O I
10.3389/fonc.2020.611467
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Philadelphia chromosome-like B-lymphoblastic leukemia (Ph-like ALL) describes a group of genetically heterogeneous, Ph-negative entities with high relapse rates and poor prognoses. A Janus-kinase-2 (JAK2) rearrangement has been reported in approximately 7% of Ph-like ALL patients whose therapeutic responses to JAK inhibitors have been studied in clinical trials. Here, we report a novel STRBP-JAK2 fusion gene in a 21-year-old woman with Ph-like ALL. Although a normal karyotype was observed, a hitherto unreported JAK2 rearrangement was detected cytogenetically. STRBP-JAK2 fusion was identified by RNA sequencing and validated by Sanger sequencing. The Ph-like ALL proved refractory to traditional induction chemotherapy combined with ruxolitinib. The patient consented to infusion of autologous chimeric antigen receptor (CAR) T cells against both CD19 and CD22, which induced morphologic remission. Haplo-identical stem cell transplantation was then performed; however, she suffered relapse at just one month after transplantation. The patient subsequently received donor lymphocyte infusion after which she achieved and maintained a minimal residual disease negative remission. However, she succumbed to grade IV graft-versus-host disease 7 months post-transplant. In conclusion, this report describes a novel STRBP-JAK2 gene fusion in a Ph-like ALL patient with a very aggressive disease course, which proved resistant to chemotherapy combined with ruxolitinib but sensitive to immunotherapy. Our study suggests that CAR T-cell therapy may be a viable option for this type of leukemia.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Immunophenotypic Comparison of Philadelphia Chromosome-Like to Philadelphia Chromosome-Positive (Ph plus ) B-Lymphoblastic Leukemia
    Choi, Sarah M.
    Shao, Lina
    Boyer, Daniel
    LABORATORY INVESTIGATION, 2018, 98 : 507 - 508
  • [2] Immunophenotypic Comparison of Philadelphia Chromosome-Like to Philadelphia Chromosome-Positive (Ph plus ) B-Lymphoblastic Leukemia
    Choi, Sarah M.
    Shao, Lina
    Boyer, Daniel
    MODERN PATHOLOGY, 2018, 31 : 507 - 508
  • [3] Identification of a Novel ZBTB20-JAK2 Fusion by Mate-Pair Sequencing in a Young Adult With B-Lymphoblastic Leukemia/Lymphoma
    Peterson, Jess F.
    Blackburn, Patrick R.
    Webley, Matthew R.
    Pearce, Kathryn E.
    Williamson, Cynthia M.
    Vasmatzis, George
    Smadbeck, James B.
    Bieliauskas, Shannon L.
    Reichard, Kaaren K.
    Ketterling, Rhett P.
    Baughn, Linda B.
    Greipp, Patricia T.
    MAYO CLINIC PROCEEDINGS, 2019, 94 (07) : 1381 - 1384
  • [4] Identification of RNPC3 as a novel JAK2 fusion partner gene in B-acute lymphoblastic leukemia refractory to combination therapy including ruxolitinib
    Chen, Xue
    Wang, Fang
    Zhang, Yang
    Ma, Xiaoli
    Liu, Mingyue
    Cao, Panxiang
    Zhou, Lin
    Wang, Lan
    Zhang, Xian
    Wang, Tong
    Liu, Hongxing
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2020, 8 (03):
  • [5] Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure
    Ding, Yang Y.
    Stern, Julie W.
    Jubelirer, Tracey F.
    Wertheim, Gerald B.
    Lin, Fumin
    Chang, Fengqi
    Gu, Zhaohui
    Mullighan, Charles G.
    Li, Yong
    Harvey, Richard C.
    Chen, I-Ming
    Willman, Cheryl L.
    Hunger, Stephen P.
    Li, Marilyn M.
    Tasian, Sarah K.
    HAEMATOLOGICA, 2018, 103 (09) : E427 - E431
  • [6] CD123 Expression in Philadelphia Chromosome-like B Acute Lymphoblastic Leukemia/Lymphoma
    Lyapichev, Kirill A.
    Sukswai, Narittee
    Angelova, Evgeniya
    Kersh, Marian J.
    Pierce, Sherry
    Konopleva, Marina
    Jain, Nitin
    Jabbour, Elias J.
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Medeiros, L. Jeffrey
    Khoury, Joseph D.
    Konoplev, Sergej
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (04): : E317 - E320
  • [7] "Russell-like" bodies in Philadelphia chromosome-positive B-lymphoblastic leukemia
    Bunting, Silvia T.
    Lew, Glen
    BLOOD, 2014, 123 (16) : 2448 - 2448
  • [8] A surrogate molecular approach for the detection of Philadelphia chromosome-like B-acute lymphoblastic leukemia
    Gupta, Dikshat Gopal
    Varma, Neelam
    Abdulkadir, Sarki Abba
    Sreedharanunni, Sreejesh
    Sachdeva, Man Updesh Singh
    Naseem, Shano
    Bose, Parveen
    Binota, Jogeshwar
    Malhotra, Pankaj
    Khadwal, Alka
    Trehan, Amita
    Varma, Subhash
    CANCER, 2024, 130 (05) : 713 - 726
  • [9] How I treat Philadelphia chromosome-like acute lymphoblastic leukemia in children, adolescents, and young adults
    Tran, Thai Hoa
    Tasian, Sarah K.
    BLOOD, 2025, 145 (01) : 20 - 34
  • [10] Targeting of a novel signaling program in Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL)
    Thomas, Kerri R.
    Allenspach, Eric J.
    James, Richard
    Tasian, Sarah
    Teachey, David
    Rawlings, David J.
    JOURNAL OF IMMUNOLOGY, 2016, 196